Anatomic segmentectomy and brachytherapy mesh implantation for clinical stage I non-small cell lung cancer (NSCLC)

• Published in: Surgery Vol. 155; no. 2; pp. 340 - 346
• Main Authors: Landreneau, Joshua P., MS, Schuchert, Matthew J., MD, Weyant, Robert, MS, Abbas, Ghulam, MD, Wizorek, Joseph J., MD, Awais, Omar, DO, Reamer, Margaret M., BSN, Luketich, James D., MD, Landreneau, Rodney J., MD
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01.02.2014
• Subjects: Aged; Brachytherapy - methods; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - radiotherapy; Carcinoma, Non-Small-Cell Lung - surgery; Female; Humans; Iodine Radioisotopes - administration & dosage; Lung Neoplasms - mortality; Lung Neoplasms - radiotherapy; Lung Neoplasms - surgery; Male; Multivariate Analysis; Neoplasm Recurrence, Local - epidemiology; Pennsylvania - epidemiology; Retrospective Studies; Surgery; Surgical Mesh; Pennsylvania
• ISSN: 0039-6060; 1532-7361
• DOI: 10.1016/j.surg.2013.06.055

Background Sublobar wedge resection is associated with an increased risk of locoregional recurrence (15–20%) compared with lobectomy for early non-small cell lung cancer (NSCLC). We have previously shown that the addition of brachytherapy mesh at the time of sublobar resection might decrease the risk of local recurrence in this setting, equivalent to that of lobectomy [Santos et al. Surgery 2003;134:691-7]. In the current study, we evaluated the impact of brachytherapy mesh implantation after formal anatomic segmentectomy on local recurrence rates in the management of clinical stage I NSCLC. Methods We undertook a retrospective review of 369 patients undergoing anatomic segmentectomy for clinical stage I NSCLC from 2002 to 2010 with ( n = 155) or without ( n = 214) the use of I131 brachytherapy mesh applied over the staple line. The primary end point was local recurrence. Secondary end points included morbidity, mortality, and recurrence-free survival. Results Patients undergoing brachytherapy mesh implantation were older (71.0 vs 69.0 years, P = .03) and had larger tumors (2.3 cm vs 2.0 cm, P = .001) compared with those treated without mesh. There were no differences noted in sex, histology, or tumor stage. Overall mortality was 1.1% (mesh, 0.6%; no mesh 1.4%). Perioperative morbidity was similar in patients receiving mesh (45.8% vs 37.4%, P  = .11). At a mean follow-up of 32.9 months, the overall local recurrence rate was 5.4% (mesh: 6.4% vs no mesh: 4.6%, P = .49). Five-year actuarial freedom from local recurrence was 92% in the mesh group, and 90% in patients undergoing segmentectomy without mesh ( P = .24). Conclusion It appears that the local recurrence noted with non-anatomic wedge resection is not an equivalent concern when anatomic segmentectomy with adequate margins are obtained. This implies that adjuvant brachytherapy after anatomic segmentectomy is not required for local control, thus avoiding the costs of radiation therapy and its associated potential toxicity. These data also suggest that proper anatomic segmentectomy alone may be associated with local recurrence rates similar to those of anatomic lobectomy in the setting of clinical stage I NSCLC.